Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model.

Interestingly, however, in the serelaxin-treated group, vascular expression of type-1 collagen declined significantly from day 9 to day 28, resulting in a highly significant decrease in collagen expression in vessels treated with serelaxin compared with vehicle, at day 28 ( Figure 5C ).

also in 132,142 other papers